The Grenoble Alpes University Hospital is a French teaching hospital built in 1974. With a total capacity of over 2 133 beds in 2020, it is the main hospital of Grenoble and Isère in France.

During the past decade, Chu Grenoble Alpes conducted 57 clinical trials. In the 10-year time frame, 57 clinical trials started and 16 clinical trials were completed, i.e. on average, 28.1% percent of trials that started reached the finish line to date. In the past 5 years, 33 clinical trials started and 9 clinical trials were completed. i.e. 27.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Chu Grenoble Alpes" #1 sponsor was "University Hospital, Grenoble" with 16 trials, followed by "Celgene" with 9 trials sponsored, "Gilead Sciences" with 6 trials sponsored, "Amgen" with 5 trials sponsored and "Pfizer" with 5 trials sponsored. Other sponsors include 33 different institutions and companies that sponsored additional 31 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Chu Grenoble Alpes" #1 collaborator was "Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG)" with 2 trials as a collaborator, "Frontier Science & Technology Research Foundation, Inc." with 2 trials as a collaborator, "Incyte Corporation" with 2 trials as a collaborator, "Merck Sharp & Dohme LLC" with 2 trials as a collaborator and "Syneos Health" with 2 trials as a collaborator. Other collaborators include 27 different institutions and companies that were collaborators in the rest 37 trials.

According to Clinical.Site data, the most researched conditions in "Chu Grenoble Alpes" are "Multiple Myeloma" (5 trials), "Crohn Disease" (3 trials), "Acute Myeloid Leukemia" (2 trials), "Atopic Dermatitis" (2 trials) and "Carcinoma, Non-Small-Cell Lung" (2 trials). Many other conditions were trialed in "Chu Grenoble Alpes" in a lesser frequency.

Most popular intervention types in "Chu Grenoble Alpes" are "Drug" (51 trials), "Other" (11 trials), "Biological" (3 trials), "Procedure" (3 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (20 trials), "Lenalidomide" (3 trials), "Ozanimod" (3 trials), "ADV7103" (2 trials) and "Azacitidine" (2 trials). Other intervention names were less common.

The vast majority of trials in "Chu Grenoble Alpes" are 75 trials for "All" genders, 2 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Chu Grenoble Alpes". undefined are not yet recruiting, 15 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 40 completed trials in Chu Grenoble Alpes, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Chu Grenoble Alpes, 5 "Phase 1" clinical trials were conducted, 23 "Phase 2" clinical trials and 32 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 4 trials that are defined as “Not Applicable".